CytRx Corporation (CYTR): Price and Financial Metrics
CYTR Price/Volume Stats
| Current price | $0.09 | 52-week high | $0.86 |
| Prev. close | $0.09 | 52-week low | $0.05 |
| Day low | $0.09 | Volume | 4,000 |
| Day high | $0.10 | Avg. volume | 99,706 |
| 50-day MA | $0.10 | Dividend yield | N/A |
| 200-day MA | $0.25 | Market Cap | 4.14M |
CYTR Stock Price Chart Interactive Chart >
CytRx Corporation (CYTR) Company Bio
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company was founded in 1985 and is based in Los Angeles, California.
Latest CYTR News From Around the Web
Below are the latest news stories about CYTRX CORP that investors may wish to consider to help them evaluate CYTR as an investment opportunity.
LadRx Corporation Announces OTCQB Ticker Change to LADXLOS ANGELES, October 05, 2022--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022. |
CytRx Corporation Relaunches as LadRx CorporationLOS ANGELES, September 23, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation. |
European Patent Office Awards CytRx Key PatentLOS ANGELES, September 07, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition. |
CytRx Welcomes Cary J. Claiborne to the CytRx Board of DirectorsLOS ANGELES, August 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the "Board"). |
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common StockLOS ANGELES, May 19, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding shares of |
CYTR Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -28.00% |
| 3-year | -88.61% |
| 5-year | -93.18% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -71.14% |
| 2020 | 503.45% |
| 2019 | -35.56% |
| 2018 | -73.37% |
Loading social stream, please wait...